Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|May 31, 2026
Dr Barlin on the Efficacy of Gotistobart Plus Pembrolizumab in Platinum-Resistant Ovarian Cancer
Author(s)Joyce Nuqui Barlin, MD
Fact checked by: Ashling Wahner , Caroline Seymour
Joyce Nuqui Barlin, MD, shares the rationale for studying gotistobart plus pembrolizumab in patients with pretreated platinum-resistant ovarian cancer.
Advertisement
“We have not yet harnessed the immune system in ovarian cancer, so this was an attempt at using a combined-modality immunotherapy to see if we could have more success.”
Joyce Nuqui Barlin, MD, a gynecologic oncologist at Women’s Cancer Care Associates, part of St Peter’s Health Partners, discussed findings from a phase 2 trial (NCT05446298) investigating gotistobart (BNT316/ONC-392) plus pembrolizumab (Keytruda) in patients with pretreated platinum-resistant ovarian cancer.
Advertisement
Related to this article
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/12
5